Amount Raised
$150 Million
Round Type
Post-IPO Equity
WatertownBiotechnologyHealth CareTherapeuticsBiopharmaDescription
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 2,769,228 shares of its common stock (“Common Stock”) at a price of $26.00 per share and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to an aggregate of 3,000,000 shares of Common Stock at a purchase price of $25.9999 per pre-funded warrant share, through a private investment in public equity (“PIPE”) financing. The Pre-Funded Warrants will have an exercise price of $0.0001 per share of Common Stock, be immediately exercisable and remain exercisable until exercised in full. Kymera anticipates the gross proceeds from the PIPE to be approximately $150.0 million, before deducting offering expenses
Quick answer
Kymera raised $150 Million in a Post-IPO Equity round, dated August 19, 2022. Kymera is based in Watertown, South Dakota, United States.
- How much did Kymera raise?
- Kymera raised $150 Million in a Post-IPO Equity round on August 19, 2022.
- What does Kymera do?
- About Kymera Therapeutics Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional..
- Where is Kymera based and how big is it?
- Kymera is based in Watertown, South Dakota, United States.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as Kymera that raised within 45 days of this round, from Fundz verified event records.
- CASI Pharmaceuticals raised an undisclosed amount on September 23, 2022.
- SpringWorks raised $225M (Post-IPO Equity) on September 7, 2022.
- Abivax raised $49M (Funding Round) on September 2, 2022.
- LumaBridge raised an undisclosed amount (Private Equity) on August 23, 2022.
- AEON Biopharma raised $30M (Funding Round) on August 3, 2022.
- Theriva Biologics raised $3M (Seed) on July 29, 2022.
Who to call at Kymera, and when
A new round usually means Kymera is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Kymera raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Kymera, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Kymera. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kymera raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Kymera raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.